Siddhartha Mukherjee (Evan Agostini/Invision/AP)

Vor leads a new pack of IPOs to price, con­tin­u­ing steady stream of com­pa­nies mak­ing leap to the Nas­daq

Six of the 10 biotechs that were ex­pect­ed to price their IPOs this week have now of­fi­cial­ly made the jump on­to the Nas­daq, con­tin­u­ing a record pace dat­ing back to 2020.

Vor Bio­phar­ma, Sid­dhartha Mukher­jee’s cell ther­a­py start­up, of­fi­cial­ly priced its 9,828,017 shares of com­mon stock Fri­day at $18 per share, rais­ing $176.9 mil­lion. Vor’s IPO, trad­ing un­der the tick­er $VOR, will close Feb. 9, with Gold­man Sachs, Ever­core ISI, Bar­clays and Stifel op­er­at­ing as bookrun­ners.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.